Drug Insight: interferon treatment in multiple sclerosis.
Drug Insight: interferon treatment in multiple sclerosis.
复制标题
药物洞察：干扰素治疗多发性硬化症。
DOI：
10.1038/ncpneuro0088
复制
发表时间：
2006
影响因子：
--
通讯作者：
Rudick,RichardA
中科院分区：
文献类型：
--
作者：
Marrie,RuthAnn;Rudick,RichardA
Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS. Between 1987 and 1997, clinical trials of three preparations of recombinant interferon-β were conducted in patients with MS, ushering in a new therapeutic era. These medications have demonstrable benefits and seem to be safe; they represent an important advance in MS treatment. All three formulations of interferon-β had modest effects on relapses and short-term progression of disability, but the effects on MRI lesion parameters were more substantial. The benefits were greater in clinically isolated syndromes and relapsing–remitting MS than in secondary progressive MS. Although these drugs have been shown to be effective, however, their long-term impact on clinically relevant disability progression is uncertain, and there are many areas of controversy in the MS field regarding the use of these products. There is still a need for more effective treatments, which might include new agents or combination therapies.
